Probiotic potential of Blautia producta L1 in mitigating Eimeria tenella-induced intestinal inflammation and dysbiosis in chickens.
Liu Jianhua J, Yuan Cheng C, Zhang Guangji G, Zhao Changjing C et al.
The capacity of Blautia to restore microbial homeostasis and attenuate intestinal inflammation highlights its potential as a promising microbial therapeutic for poultry coccidiosis. A total of 75 one-day-old male Hy-Line layer chicks were randomly allocated into five groups (n=15 per group): mock control, challenged control, B. producta L1 control, B. producta L1-challenged, and inactivated B. producta L1-challenged. From day 1 to day 22, chickens in the B. producta L1-treatment groups were orally administered either live or heat-inactivated B. producta L1 at 2 × 10⁸ CFU/mL (1 mL/bird) once daily. On day 14, chickens in the challenged groups were orally gavaged with 3 × 104 sporulated E. tenella oocysts. Protective efficacy was assessed by body weight gain, fecal oocyst out, cecal lesion score (0-4), and histopathological examination of intestinal epithelium. The anticoccidial index (ACI) was also calculated. Inflammatory cytokines including IL-1β, IL-6, TNF-α, and IL-10 were analyzed by ELISA, and mRNA expression of genes related to cecal inflammatory pathways was analyzed by qRT-PCR. The composition of the cecal microbiota was profiled using 16S rRNA gene sequencing. Supplementation with either live or heat-inactivated B. producta L1 conferred measurable protection against E. tenella challenge. Body weight gain in the live and inactivated B. producta L1-treated groups was significantly greater than that of the challenged control group (p < 0.01). Cecal lesion scores and fecal oocyst output were markedly reduced in both B. producta L1-treated groups compared with the challenged control group (p < 0.001 for both). Survival was 100% in both B. producta L1-treated groups and 86.7% (13/15) in the challenged control group. However, the between-group difference in survival was not statistically significant. The ACI values of the live and inactivated B. producta L1-treated groups were 162.0 and 151.6, respectively, corresponding to medium-effective and effective protection according to the established ACI criteria, compared with 102.2 in the challenged control group. Histopathological examination showed less epithelial degeneration, necrosis, and villus atrophy in B. producta L1-treated birds. Moreover, B. producta L1 supplementation significantly decreased serum concentrations of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α; p < 0.01) and increased the anti-inflammatory cytokine IL-10 (p < 0.05), while downregulating mRNA expression of TLR4, MYD88, NF-κB, NLRP3, P65, and Caspase-3 in cecal tissues (p < 0.05 for all). 16S rRNA gene sequencing further demonstrated that B. producta L1 increased cecal microbial richness and diversity, with higher relative abundances of beneficial genera such as Blautia and Lactobacillus and lower abundances of potentially pathogenic taxa including Salmonella, Acinetobacter, and Erysipelatoclostridium (p < 0.05). B. producta L1 moderately ameliorates E. tenella-induced pathology by helping preserve intestinal barrier integrity, dampening inflammatory responses, and reshaping the gut microbial ecosystem. These findings support B. producta L1 as a promising probiotic or postbiotic candidate for complementary control of E. tenella infection in poultry, although further benchmarking against standard anticoccidial agents and identification of active bioactive components are required.